Lexeo Therapeutics Files 8-K on Shareholder Votes
Ticker: LXEO · Form: 8-K · Filed: Jun 28, 2024 · CIK: 1907108
| Field | Detail |
|---|---|
| Company | Lexeo Therapeutics, Inc. (LXEO) |
| Form Type | 8-K |
| Filed Date | Jun 28, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
TL;DR
Lexeo Therapeutics filed an 8-K for shareholder votes - details to follow.
AI Summary
Lexeo Therapeutics, Inc. filed an 8-K on June 28, 2024, to report on matters submitted to a vote of its security holders. The filing indicates that the company is incorporated in Delaware and its principal executive offices are located at 345 Park Avenue South, Floor 6, New York, NY 10010. The report does not contain specific details about the voting matters or outcomes.
Why It Matters
This filing is a procedural update informing stakeholders about important decisions or votes taken by the company's security holders, which could impact corporate governance or future strategic directions.
Risk Assessment
Risk Level: low — This is a routine procedural filing and does not contain new financial or operational information that would immediately impact the company's risk profile.
Key Players & Entities
- Lexeo Therapeutics, Inc. (company) — Registrant
- June 28, 2024 (date) — Date of earliest event reported
- 345 Park Avenue South, Floor 6, New York, NY 10010 (location) — Principal Executive Offices
FAQ
What specific matters were submitted to a vote of Lexeo Therapeutics' security holders?
The filing states that the report concerns 'Submission of Matters to a Vote of Security Holders' but does not detail the specific proposals or resolutions voted upon.
When was the earliest event reported in this 8-K filing?
The earliest event reported is dated June 28, 2024.
What is Lexeo Therapeutics' principal executive office address?
The principal executive offices are located at 345 Park Avenue South, Floor 6, New York, New York 10010.
Under which section of the Securities Exchange Act of 1934 is this 8-K filed?
This 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is Lexeo Therapeutics' IRS Employer Identification Number?
Lexeo Therapeutics' IRS Employer Identification Number is 85-4012572.
Filing Stats: 541 words · 2 min read · ~2 pages · Grade level 12.6 · Accepted 2024-06-28 07:33:02
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share LXEO Nasdaq Glo
Filing Documents
- lxeo-20240628.htm (8-K) — 43KB
- 0000950170-24-078774.txt ( ) — 158KB
- lxeo-20240628.xsd (EX-101.SCH) — 25KB
- lxeo-20240628_htm.xml (XML) — 5KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On June 25, 2024, Lexeo Therapeutics, Inc. (the "Company") held its virtual 2024 Annual Meeting of Stockholders (the "Annual Meeting") exclusively online via live webcast. The stockholders voted on the following proposals at the Annual Meeting: Proposal 1. Election of Class I Director The Company's stockholders elected the person listed below as the Class I Director, to serve until the Company's 2027 Annual Meeting of Stockholders and until her successor is elected and qualified, or until her earlier death, resignation or removal. The final voting results are as follows: FOR WITHHELD BROKER NON-VOTE Mette Kirstine Agger 14,499,254 7,450,057 1,249,160 Proposal 2. Ratification of Appointment of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. The final voting results are as follows: FOR AGAINST ABSTAIN 23,194,982 3,088 401 For more information about the foregoing proposals, see the Proxy Statement as filed with the Securities and Exchange Commission on April 26, 2024.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Lexeo Therapeutics, Inc. Date: June 28, 2024 By: /s/ R. Nolan Townsend R. Nolan Townsend, Chief Executive Officer